AEs
| Event . | N = 26, n (%) . |
|---|---|
| Patients with any treatment-emergent AE | 26 (100) |
| Any treatment-related AE | 12 (46) |
| Patients with most common treatment-emergent AEs (>20%) | |
| Diarrhea | 16 (62) |
| aGVHD in the skin | 10 (38) |
| Abdominal pain | 6 (23) |
| Dyspnea | 6 (23) |
| Pain in extremity | 6 (23) |
| Tremor | 6 (23) |
| Weight decreased | 6 (23) |
| Any serious AE | 19 (73) |
| Any treatment-related serious AE | 3 (12) |
| aGVHD in the skin | 1 (4) |
| Chronic GVHD in the lung | 1 (4) |
| Hypersensitivity | 1 (4) |
| Any grade ≥3 AE | 19 (73) |
| Any treatment-related grade ≥3 AE | 4 (15) |
| Any AE leading to discontinuation of study treatment | 4 (15) |
| Pancreatitis | 1 (4) |
| aGVHD in the skin | 1 (4) |
| GVHD in the gastrointestinal tract | 1 (4) |
| Dyspnea | 1 (4) |
| Any deaths related to treatment | 0 |
| Event . | N = 26, n (%) . |
|---|---|
| Patients with any treatment-emergent AE | 26 (100) |
| Any treatment-related AE | 12 (46) |
| Patients with most common treatment-emergent AEs (>20%) | |
| Diarrhea | 16 (62) |
| aGVHD in the skin | 10 (38) |
| Abdominal pain | 6 (23) |
| Dyspnea | 6 (23) |
| Pain in extremity | 6 (23) |
| Tremor | 6 (23) |
| Weight decreased | 6 (23) |
| Any serious AE | 19 (73) |
| Any treatment-related serious AE | 3 (12) |
| aGVHD in the skin | 1 (4) |
| Chronic GVHD in the lung | 1 (4) |
| Hypersensitivity | 1 (4) |
| Any grade ≥3 AE | 19 (73) |
| Any treatment-related grade ≥3 AE | 4 (15) |
| Any AE leading to discontinuation of study treatment | 4 (15) |
| Pancreatitis | 1 (4) |
| aGVHD in the skin | 1 (4) |
| GVHD in the gastrointestinal tract | 1 (4) |
| Dyspnea | 1 (4) |
| Any deaths related to treatment | 0 |